Jul 09th 2012 - Edison Investment Research today published a report on Clavis Pharma entitled "Norwegian Summer". In summary, the report says:
There is now strong scientific background information on the two crucial clinical results due in Q4 on CP-4126 in pancreatic cancer and in Q1 2013 on elacytarabine in refractory and relapsed AML. The pivotal CP-4126 trial might allow a 2013 FDA submission by the global partner, Clovis. Elacytarabine will be partnered in the US if successful and marketed directly in Europe. A key commercial aspect is the potential CP-4126 formulation patent, which might extend exclusivity to 2030 to add value.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »